Postdoc-Aufenthalt am Hillman Cancer Center der Pittsburgh University 2010 – 2012.
Prüfertraining für ärztliche Staatsexamen 2015.
Klinische Schwerpunkte
Onkologische Chirurgie
Onkologische Immuntherapie
Roboter-assistierte Chirurgie im Kopf-Hals-Bereich
Wissenschaftliche Schwerpunkte
Regulatorische Immunzellen beim Kopf-Hals-Karzinom
Immunmodulation durch Chemo- und Immuntherapie
Technische Weiterentwicklungen der Roboter-Assistierten Chirurgie
Aktives Mitglied in Fachgesellschaften
Deutsche Gesellschaft für Immun- und Targeted Therapie e.V.
Deutsche Gesellschaft für Computer- und Roboterassistierte Chirurgie
Deutsche Gesellschaft für Hals-, Nasen-, Ohrenheilkunde
Gutachtertätigkeiten für Zeitschriften
Clinical Cancer Research; Oncotarget; Neoplasia; British Journal of Cancer; Int. J. Nanomedicine; J. Translational Medicine; Exp. Op. on Biological Therapy; Cytometry A, Head & Neck; Oral Oncology; Cancer Chemotherapy and Pharma; Medical Oncology; Eur. Archives ORL; IJMRCAS; Eur. J. Medical Research; Biomedical Engineering; Annals of ORL; Oncotargets and Therapy
Gutachtertätigkeit für Institutionen
Swiss Cancer League
Czech Health Research Council
Medical Research Council (London, UK)
dt. Gesellschaft für Computer- und Roboter-assistierte Chirurgie
Auszeichnungen, Stipendien und Preise
Anton-von-Tröltsch-Preis der dt. HNO-Gesellschaft, Bonn, 2017
Wirtschafts-Wissenschaftspreis der Universität Ulm, 2015.
Preis der dt. Gesellschaft für Immun und Targeted Therapy, München, 2015.
Karl-Preis der Stiftung Tumorforschung Kopf-Hals, Wiesbaden, 2014.
Reise-Stipendium der ‘American Head and Neck Society’, Arlington, 2010.
Klinische Studien
IRX-2 (principal investigator): Randomized phase II trial of neoadjuvant and adjuvant therapy with the IRX-2 regimen in patients with newly diagnosed squamous cell carcinoma of the oral cavity (NCT02609386). Start: 2018.
MAGE-Vaccination (sub PI): Randomized, placebo-controlled clinical trial with GL-0817, a MAGE-A3 immunomodulatory cancer therapeutic vaccine, for the patients with high-risk squamous cell carcinoma of the oral cavity (NCT02873819). Start: 2018.
Keynote 412 (sub-investigator): Phase III Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (NCT03040999). Duration 2017-2021.
CheckMate 651 (sub-investigator): Study of nivolumab in combination with ipilimumab compared to the standard of care as first line treatment in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (NCT02741570). Duration: 2016-2020.
Keynote 012 (sub-investigator): Phase III randomized trial of prembolizumab vs. standard treatment in subjects with recurrent or metastatic head and neck cancer (NCT01848834). Duration: 2015 – 2016.
Flex (principal investigator): An interventional multicenter post-market phase I clinical study of the Medrobotics Flex™ system used for accessing and visualizing the oropharynx and hypopharynx during transoral procedures. (NCT02262247). Duration: 2014 – 2015.
Breg (principal investigator): Anon-interventional, single center study. Examination of regulatory B cells in tumor tissue, metastasis and peripheral blood obtained from patients with head and neck cancer. Start: 2014.
AL1201av (sub-investigator): Open label phase II multicentre clinical trial with an allergoid grass pollen preparation in adult patients with IgE mediated allergic rhinitis (EudraCT 2012-001914-41). Sponsor: Allergopharma Joachim Ganzer KG. Duration: 2012 – 2013.
Soccer (sub-investigator): Examination of symptom control in patients with recurrent and/or metastatic squamous cell head and neck cancer during first-line therapy with Erbitux (EMR062202-542). Sponsor: Merck Serono. Duration 2012 – 2018.
Lux-Head&Neck-II (sub-investigator): A phase III trial of afatinib (BIBW 2992) versus placebo for the treatment of head and neck squamous cell cancer after treatment with chemo-radiotherapy (NCT01345669). Sponsor: Boehringer-Ingelheim. Duration: 2011 – 2016.
PD-1-Inhibitor Pembrolizumab (sub-investigator): A Phase III randomized trial of Prembolizumab vs. standard Treatment in subjects with recurrent or metastatic head and neck cancer. Sponsor: Merck-MSD. Duration: 5/2015 – 7/2017.
